Neumora Therapeutics, Inc. (NASDAQ:NMRA)
| Market Cap | $63.01M-85.7% |
| Revenue (ttm) | $0 |
| Net Income | -$190.43M+19.4% |
| EPS | -$1.06+27.9% |
| Shares Out | 188.69M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,059,349 |
| Open | $0.34 |
| Previous Close | $0.35 |
| Day's Range | $0.30 - $0.36 |
| 52-Week Range | $0.30 - $3.65 |
| Beta | 3.14 |
| Analysts | Buy |
| Price Target | $4.50(+1247.71%) |
| Earnings Date | Mar 29, 2027 |
About NMRA
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 29, 2027Earnings report
$NMRA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in NMRA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NMRA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NMRA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NMRA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NMRA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NMRA
| VTIVanguard Morningstar Total Stock Market ETF | $994.13K |
| IWMiShares Russell 2000 ETF | $876.27K |
| VXFVanguard Extended Market ETF | $413.49K |
| IWOiShares Russell 2000 Growth ETF | $370.94K |
| VTWOVanguard Russell 2000 ETF | $222.32K |
| IBBiShares Biotechnology ETF | $207.97K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from NMRA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst price target cuts and downward valuation revision dominate coverage, though Guggenheim maintains Buy rating despite cutting target to $8 from $14.
